产品名称

WZ 4002

产品货号

Axon 1506 CAS [1213269-23-8] MF C25H27ClN6O3MW 494.97 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description A mutant-selective EGFR kinase inhibitor against EGFR T790M; a potential agent for some drug-resistant non-small cell lung cancers References Certificates Categories Extra info W Zhou et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462, 1070-1074. Y Sakuma et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Laboratory Investigation 2012, 92, 371-383. Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology EGFR JAK-STAT RTK class I; EC 2.7.10.1 EGFR kinase inhibitor (T790M specific) Chemical name N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazine-1-yl)phenylamino)pyrimidin-4yloxy)phenyl)acrylam Parent CAS No. [1213269-23-8] Order Size Unit Price Stock 5 mg €70.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

WZ 4002

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 1506

CAS [1213269-23-8]

MF C25H27ClN6O3
MW 494.97

Purity: 99%
Soluble in 0.1N HCl(aq) and DMSO

WZ 4002

Description

A mutant-selective EGFR kinase inhibitor against EGFR T790M; a potential agent for some drug-resistant non-small cell lung cancers

W Zhou et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462, 1070-1074.

Y Sakuma et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Laboratory Investigation 2012, 92, 371-383.

Angiogenesis Cell Signaling & Oncology EGFR JAK-STAT RTK class I; EC 2.7.10.1

EGFR kinase inhibitor (T790M specific)

Chemical name

N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazine-1-yl)phenylamino)pyrimidin-4yloxy)phenyl)acrylam

Parent CAS No.

[1213269-23-8]

产品资料